Monday, June 15, 2026

North Korea Holds Fire on Seoul, Shifts ICBM Threat Toward U.S.

North Korea has intensified rhetoric against South Korea, citing a drone incident while shifting focus to a new ICBM launch aimed at the U.S.

Alarming Threats to NewJeans: Agency and Police Step Up

Amidst the rising controversy caused by a...

Kim Jong Un Expected to Travel to China by Armored Train; Beijing Arrival Likely Tuesday Ahead of Victory Day

Kim Jong Un is set to travel to China by private train, a journey of 16-20 hours, ahead of Victory Day celebrations.

Tag: biosimilar

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Daewoong Pharmaceutical Expands Biosimilar Push With Dupixent Copy Deal and Global CDMO Partnership

Daewoong Pharmaceutical partners with Chime Biologics to develop a Dupixent biosimilar, enhancing its global biosimilar business expansion.

A 90-Minute Cancer Infusion Could Soon Be Cut to 5 Minutes—and Celltrion Wants to Lead It

Celltrion has applied for EMA approval of Herzuma SC, a new breast cancer treatment, enhancing drug delivery and patient convenience.

Stoboclo: How This New Osteoporosis Treatment Achieved 11.8 Billion KRW in Sales in Just One Year

Daewoong Pharmaceutical's Stoboclo, a biosimilar for osteoporosis, achieved 11.8 billion KRW in sales in its first year, marking rapid growth.

Celltrion’s CT-P55: What Changes to FDA Clinical Trials Mean for Biosimilarity with Cosentyx?

Celltrion has applied to the FDA for changes to its Phase 3 trial of CT-P55, reducing participants to 153 to assess biosimilarity to Cosentyx.

How Celltrion’s Herceptin Biosimilar Herzuma Achieved 74% Market Share in Japan: A Game Changer for Cancer Treatment

Celltrion's Herzuma biosimilar captures 74% of Japan's trastuzumab market, enhancing patient access and leveraging favorable policies.

Samsung Bioepis Secures U.S. Approval for Pen-Style Stelara Biosimilar, Setting a Market First

Samsung Bioepis receives FDA approval for Epyztek, the first pre-filled pen for autoimmune treatments, enhancing patient convenience.

Chong Kun Dang Wins European Phase 1 Approval for Dupixent Biosimilar: Advancing CKD-706’s Global Development

Chong Kun Dang's CKD-706 biosimilar for Dupixent received Phase 1 trial approval in Europe, aiming to expand treatment options for inflammatory diseases.

FDA Ruling Paves Way for Pharmacy Substitution of Yuflyma for Humira

Celltrion's Yuflyma receives FDA approval for interchangeability with Humira, boosting market confidence and distribution in the U.S.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.